Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 226 (LINC00226) is a human long non-coding RNA (lncRNA) that does not encode a protein but plays a regulatory role at the genomic and epigenetic levels[1][3][5]. It is located on chromosome 14q32.33 and consists of at least two exons[1][7]. LINC00226 has been implicated in diverse biological processes, including regulation of gene expression and chromatin structure, and is associated with various pathological conditions such as cancer, where its altered copy number or expression can influence tumorigenesis and potentially serve as a biomarker for diagnosis or prognosis. While it shows relevance in cancers such as glioblastoma, penile cancer, and chronic lymphocytic leukemia, as well as a potential role in male infertility, there is no strong evidence that it functions as a direct therapeutic target (e.g., not a receptor, enzyme, or transporter), and there are no known drugs targeting LINC00226 currently[3][5][7]. Its specific mechanisms of action in disease contexts remain under investigation, and further studies are needed to clarify its clinical implications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 226 (LINC00226).